The Medicines Patent Pool (MPP) has signed agreements with ten patent holders for 13 HIV antiretrovirals, one HIV technology platform, a tuberculosis treatment and three hepatitis C direct-acting antivirals. 22 generic manufacturers and product developers have now signed MPP sublicensing agreements.
Overview of all licensing and sublicensing agreements
Generic competition is making a difference in fostering lower prices and improving treatment coverage. Generic partners have distributed 31.4 million patient-years of HIV and hepatitis C products, saving international procurers USD 1.44 billion (January 2012-December 2019).
Slide decks highlighting progress of MPP’s generic partners in developing, manufacturing and supplying MPP-licensed medicines, are available for:
(Last update: April 2020 – data as of December 2019)
Key
HIV Hepatitis C Tuberculosis| Products | Products | Companies developing the product | Pending Approval | Ready to Supply | Countries where | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO-PQ | USFDA | WHO-PQ Approved | USFDA Approved | ERP Approved | Product is Filed | Product is Approved | Product is Sold | Map View | |||
12 | 4 | 2 | 5      | 5   | 1  | 19
| 40
| 86
|  | ||
15 | 6 | 5 | 5  | 5  | 21
| 39
| 65
|  | |||
10 | 3 | 1 | 18
| 8
| 3
|  | |||||
2 | 1 | 1
|  | ||||||||
4 | 2 | 13
| 7
| 1
|  | ||||||
3 | 1 | 1
|  | ||||||||
7 | 3 | ||||||||||
5 | 2 | 2 | 3 | 13
| 32
| 77
|  | ||||
DRV/r  | 1 | 1 | 1 | 8
|  | ||||||
4 | 1 | 2 | 4
| 56
| 91
|  | |||||
1 | 1 | 2
| 11
| 12
|  | ||||||
1 | 1 | ||||||||||
DAC  | 5 | 2 | 3 | 1 | 23
| 28
| 25
|  | |||
DAC+SOF | 3 | 1 | 1 | 1 | 15
| 7
| 5
|  | |||
[WHO-PQ] Prequalification from the World Health Organization | [USFDA] U.S. Food and Drug Administration | [ERP] Expert Review Panel led by the Global Fund
Last update of the table: April 2020 (data as of December 2019)
Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions